Impression taking for Implants:
Periodontal disease prevalence is underestimated by 50%
Research published in the Journal of Dental Research from the Center of Disease control (CDC) and the American Academy of Periodontology (AAP) suggests that the prevalence of periodontal disease may have been underestimated by as much as 50 percent. The implication is that more American adults may suffer from moderate to severe gum disease than previously thought.
Orthodontics is naturally a long (usually 2 year) commitment. A simple surgical procedure in which the cortical bone between the roots is altered, there is a significant reduction in the active orthodontic cases. A newly published article from USC has shown that when corticotomy is combined with grafting, the orthodontic phase could end in one third of it's expected time (8 months). Please refer to the article below.
Soft tissue enhancement around dental implants:
The final aesthetics of dental implants depends on several factors. One of the most important factors is the soft tissue status. The article below shows several approaches in enhancing the appearance of dental implants in cases of asymmetry, ridge collapse, lack of papillae and more.
The link between periodontal disease and cardiovascular disease:
An joint position paper published in 2009 between American Academy of Periodontology and American Society of Cardiology established a link between periodontal disease and Atherosclerotic Cardiovascular disease. Please refer to the statement published between these institutions.
Lasers in treating periodontitis:
The official position of the American Academy of Periodontology is that there are no established evidence in using lasers as an adjunct in treating periodontitis. The paper below published as an official position of the AAP, reviews the research done in this field.
ADA Journal Feb/2011
Is a custom-fit tray for delivery of Materials established by the dentist in treatment of periodontal disease. The FDA clearance of the device did not determine that the tray has been proven safe or that it provides any benefits in treating periodontal disease. Numerous clinical studies have suggested that topically applied medicines do not reach the source of periodontal infection
Local delivery of antimircobial agents (Atridox, Arestin, Periochip)
Recent systematic reviews report that modest additional probing depth (PD) reductions in the range of 0.25 mm to 0.5 mm were achieved when LDAs were used as an adjunct to SRP in pockets ‡5 mm. However, even when the differences were statisti- cally significant, the additional improvement in PD was a fraction of the reported mean 1.45 mm PD reduction achieved by SRP alone. Effects on clinical attachment level gains were smaller and statistical significance less common. In many studies, repeated LDA applications were compared to a single episode of SRP. It should be noted that these reviews included a number of antimicrobial agents not currently sold in the United States. Antimicrobial agents for local delivery currently sold in the United States include: ArestinÒ (1 mg minocycline microspheres), AtridoxÒ (10% doxycycline hyclate in a bioabsorbable polymer), and PerioChipÒ (2.5 mg chlorhexidine in gelatin matrix).The existing data appear insufficient to conclude that adjunctive sustained or controlled release LDA treatment can either reduce the need for surgery or improve long-term tooth retention, or is cost effective.